Clinical trials
Hormone Sensitive Prostate Cancer clinical trials
Below are recruiting hormone sensitive prostate cancer clinical trials, each written for real people, not researchers. We’re tracking 106 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07698535RecruitingPhase 2
Blood test to guide early stopping of prostate cancer therapy
This trial uses a blood test to measure tumor DNA and see if men with advanced prostate cancer can safely stop treatment with a drug called 177Lu-PSMA-617 earlier than usual, or switch to chemotherapy. It may help reduce side effects while still controlling the cancer.
Seattle, WashingtonAges 18 years+ - NCT06632977RecruitingPhase 2
Matching targeted treatments to your prostate cancer's genetics
This trial is testing whether matching your cancer's specific genetic changes to a targeted treatment can help control metastatic prostate cancer that has stopped responding to standard hormone therapy and chemotherapy. You may receive a drug, a radioactive treatment, or a combination based on your tumor's molecular profile.
Birmingham, AlabamaAges 18 years+ - NCT07493512RecruitingPhase 1
Study of xaluritamig for metastatic prostate cancer
This trial tests a new drug called xaluritamig for men with metastatic prostate cancer that is resistant to hormone therapy. It is designed for those who have already tried certain hormone pills and one type of chemotherapy, and aims to see if the drug can shrink tumors or slow cancer growth.
Denver, ColoradoAges 18 years+ - NCT07213674RecruitingPhase 3
A study of xaluritamig plus abiraterone for prostate cancer
This trial tests a new combination of two drugs (xaluritamig plus abiraterone) for men with a type of advanced prostate cancer that is no longer responding to hormone therapy but has not yet been treated with chemotherapy. The goal is to see if this combination works better than the standard options your doctor might choose.
Goodyear, ArizonaAges 18 years+ - NCT06879041RecruitingPhase 1
Study of a radiation drug for advanced prostate cancer
This trial tests a new drug that delivers radiation directly to cancer cells. It is for men with metastatic castration-resistant prostate cancer that has progressed after other treatments.
Palo Alto, CaliforniaAges 18 years+ - NCT04986423RecruitingPhase 2
Add ZEN003694 to enzalutamide for resistant prostate cancer
This Phase 2 study tests whether adding ZEN003694 to enzalutamide works better than enzalutamide alone in men whose prostate cancer has spread and is no longer controlled by hormone lowering treatments. It focuses on people who either did not respond well to abiraterone (poor responders) or did respond (responders), then compares outcomes between treatment groups.
Los Angeles, CaliforniaAges 18 years+ - NCT05361798RecruitingPhase 2
Testing immune response after prostate radiation with or without a drug
This study checks how your immune system’s cancer-fighting cells change after stereotactic body radiation (SBRT) to the prostate. It compares SBRT alone versus SBRT plus an immunotherapy drug (PDS01ADC) in men with intermediate- or high-risk localized prostate cancer treated with hormone therapy (ADT).
Bethesda, MarylandAges 18 years+ - NCT06990880RecruitingPhase 1/Phase 2
A study of a new drug for advanced prostate cancer
This study tests an experimental drug, alone or with other treatments, for men with advanced prostate cancer that has stopped responding to standard therapies. The goal is to see if it can shrink tumors or slow the disease.
Phoenix, ArizonaAges 18 years+ - NCT06842498RecruitingPhase 2
FG-3246 for advanced prostate cancer
This trial tests a new drug called FG-3246, which targets a protein (CD46) on prostate cancer cells. It's for men with advanced prostate cancer that has spread and stopped responding to standard hormone therapy, and who have had limited prior treatments.
Goodyear, ArizonaAges 18 years+ - NCT05209243Recruiting
Treating limited-spread prostate cancer with radiation plus hormone therapy
This trial studies whether adding focused radiation (SBRT) to hormone therapy can control prostate cancer that has spread to only a few places. It aims to help people with early “oligometastatic” prostate cancer by improving disease control while limiting treatment side effects.
MadridAges Any age - NCT07611110RecruitingPhase 3
AZD2265 vs standard care for advanced prostate cancer
This trial tests a new cancer-fighting drug called AZD2265 against standard treatment for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. You may qualify if your cancer previously responded to PSMA-targeted radiation treatments but is now growing again.
Dothan, AlabamaAges 18 years+ - NCT07129551Recruiting
PSMA-guided surgery for prostate cancer with lymph node spread
This study looks at how well a special type of surgery, guided by PSMA-PET scans, works for men with prostate cancer that has spread to a small number of lymph nodes in the pelvis. It aims to improve outcomes and quality of life.
Hamburg, Free and Hanseatic City of HamburgAges 18–78 - NCT04704505RecruitingPhase 2
Testosterone-like treatment plus radium for bone-spread prostate cancer
This trial studies whether adding a testosterone-related therapy (BAT) to radium-223 can better control prostate cancer that has spread mainly to the bones. It may help shrink tumors in the bone and slow PSA rises, which are a common marker of prostate cancer activity.
Baltimore, MarylandAges 18 years+ - NCT07224009RecruitingPhase 2
Low dose naltrexone for fatigue in prostate cancer on hormone therapy
This trial tests if a low dose of the drug naltrexone can help reduce fatigue in men with prostate cancer who are currently receiving hormone therapy (ADT). It may offer a new way to manage tiredness during treatment.
Little Rock, ArkansasAges 18 years+ - NCT06594926RecruitingPhase 2
Bipolar androgen therapy for prostate cancer without metastases
This trial tests a treatment called bipolar androgen therapy for men with prostate cancer that has not spread to other parts of the body and is still growing despite taking darolutamide. The goal is to see if this therapy can help control the cancer.
Garran, Australian Capital TerritoryAges 18 years+ - NCT04271579Recruiting
Surgery for early prostate cancer spread seen on PSMA PET
This trial studies whether operating on a small, one-sided (unilateral) area of prostate cancer spread in the pelvic lymph nodes—found on a PSMA PET scan—can help control recurrence. It’s meant for people whose PSA is still low and whose spread appears limited on the scan.
HamburgAges 18–75 - NCT05983432RecruitingPhase 1
Study of BL-B01D1 for advanced lung and other solid tumors
This trial tests an experimental drug called BL-B01D1 for people with several types of advanced solid tumors, especially non-small cell lung cancer and breast cancer. It's designed for those whose cancer has continued to grow after standard treatments.
Beverly Hills, CaliforniaAges 18 years+ - NCT07226713RecruitingPhase 2
Pacritinib for advanced prostate cancer after hormone therapy failure
This trial tests a drug called pacritinib for men with metastatic prostate cancer that has stopped responding to hormone therapies. It aims to see if blocking the JAK2/STAT5 pathway can slow cancer growth.
Milwaukee, WisconsinAges 18 years+ - NCT06236789Recruiting
Ifosfamide for men with advanced prostate cancer
This trial is studying whether the chemotherapy drug ifosfamide (given with mesna to protect the bladder) can help men whose prostate cancer has spread and is no longer controlled by hormone therapy. It is for men who have already tried the chemotherapy docetaxel.
SeoulAges 19 years+ - NCT07572760Recruiting
Power Training for Men With Advanced Prostate Cancer
This study tests whether light-to-moderate strength training exercises can help men with advanced prostate cancer that has spread to bones or lymph nodes. The goal is to see if exercise improves physical strength and quality of life while you continue your cancer medications.
San Vicent del Raspeig, AlicanteAges 50 years+ - NCT07717268RecruitingPhase 2
Stereotactic Radiation Plus New Hormone Therapy for Prostate Cancer
This trial tests a targeted, high-dose radiation therapy (SBRT) plus a newer hormone drug (abiraterone or enzalutamide) for men whose prostate cancer has spread to a small number of spots (5 or fewer) and is no longer controlled by standard hormone therapy.
Zaragoza, AragonAges Any age - NCT07476001RecruitingPhase 2
High-dose testosterone and PSMA-targeted radiation for prostate cancer
This trial tests whether a short course of high-dose testosterone followed by a radioactive drug (PSMA-617) can help men with advanced prostate cancer that has stopped responding to hormone therapy. The goal is to make cancer cells more sensitive to the radiation.
Tampa, FloridaAges 18 years+ - NCT07218666RecruitingPhase 2
Zanzalintinib for aggressive prostate cancer
This trial tests a new drug, zanzalintinib, in men with a fast-growing type of prostate cancer that has spread and stopped responding to standard hormone therapies. It aims to see if the drug can help shrink tumors or slow the disease.
Milwaukee, WisconsinAges 18 years+ - NCT06112990RecruitingPhase 3
Creatine and exercise to keep muscles strong in prostate cancer
This trial tests if taking creatine plus doing resistance exercises at home can help men with prostate cancer maintain muscle mass and slow cancer growth. You would take creatine or a placebo for 52 weeks and do simple strength exercises twice a week.
Salt Lake City, UtahAges 18 years+
Hear when a new Hormone Sensitive Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hormone sensitive prostate cancer?
- Yes. Clin2 currently lists 106 recruiting hormone sensitive prostate cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hormone sensitive prostate cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hormone sensitive prostate cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
- Castration Sensitive Prostate Cancer
- Castrate Sensitive Prostate Cancer
- Metastatic Castration-resistant Prostate Cancer
- Metastatic Prostate Cancer
- Prostate Cancer (Adenocarcinoma)
- Breast Cancer Early Stage Breast Cancer (Stage 1-3)
- Stage IVB Prostate Cancer AJCC v8
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.